Sep 10, 2012, 10.56 AM | Source: Moneycontrol.com
Shares of Cipla, a drug producer, touched a fresh 52-week high of Rs 395.45 on Monday and rose for the second consecutive session after the company won patent case against Roche.
Roche had filed suit against Cipla on drug Tarceva in 2008. Delhi HC said Cipla’s product Erlocip could be marketed.
At 10:49 hours IST, the share was trading at Rs 392.00, up 0.32% with volumes of 93,700 equity shares.
On Saturday, the share jumped 2.65% to close at Rs 390.75. Market capitalisation of the company currently stands at Rs 31,474.52 crore.
Analysts doubt veracity of US API import ban report
A report today said the US government has made it
Cipla Q3 results on Feb 10, 2016
Cipla board meeting will be held on February 10, 2
Cipla patriarch Y K Hamied increases stake in co to over 20%
Y KHamied (80), who is the Non-Executive Chairman
Super Six short term picks for February 1
Manas Jaiswal of manasjaiswal.com advises buying I
Cipla top bet from pharma space, says Jai Bala
Jai Bala of Cashthechaos.com is of the view that C
Cipla gets CCI nod to sell 26% in consumer healthcare biz
In November last year, the company signed an agree
Buy United Breweries; short Cipla: Gaurav Bissa
Gaurav Bissa of LKP Securities recommends buying U
Sensex, Nifty flat; L&T, Adani, Cipla top gainers
L&T, Adani Ports, Cipla, Lupin and Wipro are top g